MedMira Inc V.MIR

Alternate Symbol(s): MMIRF

Healthcare Medical Devices

MedMira Inc. is a Canada-based developer and manufacturer of Rapid Vertical Flow (RVF) diagnostics. The Company's tests provide hospitals, labs, clinics and individuals with instant disease diagnosis, such as human immunodeficiency virus (HIV), syphilis, hepatitis, and SARS-CoV-2, in three steps. The Company is engaged in the business of research, development and manufacturing of rapid diagnostics and technologies. Its research is focused on specific areas of the broader diagnostics market, namely the rapid, point-of-care, and in vitro sectors. Its tests are sold globally under the REVEAL, REVEALCOVID-19, Multiplo and Miriad brands. Based on its patented Rapid Vertical Flow Technology, the Company's rapid HIV test has regulatory approvals in Canada, the United States, China and the European Union. Its manufacturing facilities are located in Halifax, Nova Scotia, Canada. It provides access to its RVF Technology for researchers, developers, and biotech companies on a license basis.

TSXV:MIR - Post by User

MedMira Inc > friday at the fda

<< Previous

Bullboard Posts

Next >>

Post by goldyhawkon Jan 08, 2021 12:54pm

130 Views

Post# 32254806

friday at the fda

Thread

Tweet

Dr. Stephen M. Hahn

@SteveFDA

28m

 																	The FDA will continue to monitor SARS-CoV-2 genetic viral variants to ensure authorized tests continue to provide accurate results for patients.

 																				Quote Tweet

U.S. FDA

@US_FDA

 																							· 																							 																								29m 																						

 																							FDA is alerting clinical lab staff & health care providers that it is monitoring the potential impact of viral mutations, including an emerging variant from the United Kingdom known as the B.1.1.7 variant, on authorized SARS-CoV-2 molecular tests. https://fda.gov/news-events/press-announcements/fda-issues-alert-regarding-sars-cov-2-viral-mutation-health-care-providers-and-clinical-laboratory…

 																							Show this thread

2

7

Dr. Stephen M. Hahn

@SteveFDA

28m

 																	We are working with authorized test developers and reviewing incoming data to ensure that health care providers and clinical staff can quickly and accurately diagnose patients infected with SARS-CoV-2, including those with emerging genetic variants.

1

9

 									Replies

Christian

@b2e9f523

6m

 																	Replying to 																	 																		@SteveFDA

So MedMira's enhanced REVEALCOVID-19 PLUS Total Antibody Test for the simultaneous detection of antibodies to both Nucleocapsid and the the new mutations' Spike proteins will help significantly, right?  																		@medmira
 																		@webbdiagnostic